Vertex Pharmaceuticals

Vertex is based in Boston. Trikafta, a triple combination of elexacaftor, tezacaftor, and ivacaftor, became the standard modulator for eligible cystic fibrosis patients, and Alyftrek is the newer once-daily triple.

Earlier combinations, Kalydeco, Orkambi, and Symdeko, established the franchise, and there is still no second company with a modulator that covers the same mutations. National payers, including NICE-style health technology bodies in Europe, decide the price at which that near-universal eligible population is treated.

Casgevy, the CRISPR gene-editing therapy Vertex shares with CRISPR Therapeutics, is a one-time treatment for sickle cell disease and beta thalassemia at a handful of authorized centers. Journavx, the suzetrigine pill for acute pain, is a separate bet aimed at hospitals that want a non-opioid option after surgery.

CFTR modulator patents and the absence of a like-for-like rival define the cystic fibrosis market.

Country-by-country reimbursement decides whether eligible patients outside the United States actually receive Trikafta or Alyftrek.

Casgevy capacity is the number of transplant-style centers qualified to deliver it.

A person with cystic fibrosis who responds to Trikafta builds a life around uninterrupted specialty pharmacy shipments.

Hospitals evaluating Journavx compare it with cheap generic analgesics, so protocol placement matters more than a consumer ad.